Drug Profile


Alternative Names: Cerdelga; Eliglustat tartrate; Genz-112638

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Michigan
  • Developer Sanofi Genzyme
  • Class 2 ring heterocyclic compounds; Amides; Pyrrolidines; Small molecules
  • Mechanism of Action Glucosylceramide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gaucher's disease type I
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gaucher's disease type I

Most Recent Events

  • 31 May 2017 NICE publishes final guidance recommending eliglustat to be funded by the National Health Service for Gaucher's disease type I in the UK
  • 01 May 2017 Registered for Gaucher's disease type I (Treatment-naïve) in Canada (PO)
  • 01 Jan 2017 Sanofi completes a phase I pharmacokinetics trial for Gaucher Disease in USA (NCT02536937)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top